SCHEMBL1696407

SCHEMBL1696407

CCCc1cccc(C(=O)NCCC(C)C)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.54
NPC1 O15118 4/20 0.52
RAB9A P51151 4/20 0.52
GAA P10253 1/20 0.51
KMT2A Q03164 1/20 0.51
HSD17B10 Q99714 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
LMNA P02545 3/20 0.51
KAT6A Q92794 1/20 0.50
TP53 P04637 1/20 0.48
ROCK2 O75116 1/20 0.48
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15676734 0.89 SMN1; SMN2 (0.55) SMN1; SMN2NPC1RAB9AGAAKMT2A
SCHEMBL3046094 0.88 SMN1; SMN2 (0.51) SMN1; SMN2NPC1RAB9AGAAKMT2A
SCHEMBL14233690 0.87 L3MBTL1 (0.67) SMN1; SMN2NPC1RAB9AL3MBTL1LMNA
SCHEMBL1690498 0.85 SMN1; SMN2 (0.51) SMN1; SMN2NPC1RAB9AGAAKMT2A
SCHEMBL14233914 0.84 KAT6A (0.58) SMN1; SMN2NPC1RAB9AGAAKMT2A
SCHEMBL18717445 0.83 SMN1; SMN2 (0.48) SMN1; SMN2NPC1RAB9AGAAKMT2A
SCHEMBL1696410 0.83 NPC1 (0.72) SMN1; SMN2NPC1RAB9AKMT2ALMNA
SCHEMBL1928098 0.82 NPC1 (0.67) SMN1; SMN2NPC1RAB9AKMT2ALMNA
SCHEMBL3199651 0.82 SMN1; SMN2 (0.55) SMN1; SMN2NPC1RAB9AL3MBTL1LMNA
SCHEMBL12760632 0.81 L3MBTL1 (0.72) SMN1; SMN2NPC1RAB9AGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088758-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-04-12 US disclosed
US-7453002-B2 thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088758-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS F12, F11, F5 SMN1; SMN2 4322/4885NPC1 3968/4885RAB9A 818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.